
|Articles|January 15, 2004
Fixed-combination drug beneficial in glaucoma therapy
The fixed combination of timolol-dorzolamide (Cosopt, Merck) can be beneficial in glaucoma therapy for several reasons: prescribed in conjunction with a single agent such as a prostaglandin analog, it may achieve a greater reduction in the patient's IOP than the single agent alone, and it can improve compliance, according to two glaucoma experts.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Study identifies corneal endothelial changes following mRNA COVID-19 vaccination
2
SpyGlass Pharma randomizes first patients in 2 phase 3 clinical trials of the BIM-IOL System
3
STAAR, Broadwood reach cooperation agreement, restructure board after terminated Alcon deal
4
Q&A: Understanding Medicare payment shifts in eye care
5














































